IRF5

IRF5 rs10488631 — The Interferon Amplifier Haplotype

Interferon Regulatory Factor 5 (IRF5) is a master transcription factor that drives type I interferon production and proinflammatory cytokine secretion. When immune cells detect viral or self-nucleic acids through toll-like receptors 7 and 9 | Pattern recognition receptors in endosomes that detect single-stranded RNA and CpG DNA, respectively, IRF5 translocates to the nucleus and activates genes encoding IFN-α, IFN-β, TNF-α, IL-6, and IL-12. The rs10488631 variant is a non-coding SNP in the 3' region of IRF5 that serves as a key tag for a risk haplotype | A set of nearby variants inherited together as a block; rs10488631 is representative of one of three independent IRF5 haplotype blocks associated with increased IRF5 expression and broad autoimmune disease susceptibility. Individuals carrying the C allele have measurably elevated interferon output that correlates directly with autoimmune disease risk.

The Mechanism

The rs10488631 variant itself lies downstream of the IRF5 coding sequence, but the C allele tags a haplotype block containing a 30-bp in-frame insertion/deletion in exon 6 | This INDEL falls in a proline-, glutamic acid-, serine- and threonine-rich domain known to influence protein stability and function in the IRF family. The exon 6 INDEL affects the proline-rich domain that modulates IRF5 protein stability and transcriptional activity. The haplotype bearing rs10488631-C includes risk variants at three independent functional sites: the exon 1B splice site (rs2004640), the exon 6 INDEL, and a 3' polyadenylation signal variant | The rs10954213 variant disrupts a canonical polyA+ signal, causing use of a distal polyadenylation site that alters mRNA length and stability. Together, these produce an IRF5 transcript that is more stable and more highly expressed.

Functional studies in European lymphoblastoid cell lines confirmed that the C allele of rs10488631 independently correlates with increased IRF5 mRNA, IFN-α, and IFN-inducible chemokine expression | Bonferroni-corrected p=0.0005 for increased IRF5 expression; p=0.01 for IFN-α. The biological consequence is a lower threshold for triggering and sustaining the interferon response. In lupus patients, this elevated baseline is amplified dramatically when autoantibodies are present: among SLE patients positive for anti-RBP or anti-dsDNA antibodies, those carrying the IRF5 risk haplotype showed significantly elevated median serum IFN-α activity (P=0.012) | Risk/neutral genotype patients vs. protective/protective genotype patients in autoantibody-positive subset compared to those with protective haplotypes — a striking gene-environment interaction within the immune system itself.

The Evidence

The strongest evidence for rs10488631 comes from systemic lupus erythematosus. A landmark 14-cohort European study encompassing 1,383 SLE cases and 1,614 controls identified rs10488631-C as the susceptibility-tagging SNP at the IRF5 locus | P<10⁻¹⁷; the susceptibility haplotype is driven by epistasis among three functional IRF5 polymorphisms; none had an independent effect on its own. The earlier PNAS study by Graham et al. reported a transmission/untransmission ratio of ~1.8 (P~1.2×10⁻⁷) in a family-based analysis | Haplotype group containing rs10488631 showed T/U≈1.8 across 2,188 case and 3,596 control chromosomes for the risk haplotype in lupus. A subsequent Swedish case-control study by Sigurdsson et al. found OR=2.07 (95% CI 1.63–2.62, P=9.4×10⁻¹⁰) for rs10488631-C — one of the strongest non-HLA effect sizes in autoimmune genetics.

For systemic sclerosis (scleroderma), a large European case-control study of 3,361 SSc patients and 4,012 controls | Five countries: Spain, Germany, the Netherlands, Italy, and UK found rs10488631-C associated with global SSc susceptibility at OR=1.63 (P=7.53×10⁻²⁰). The three-SNP IRF5 haplotype (including rs2004640 and rs4728142) further strengthened the association to OR=1.75 (P=9.04×10⁻²²), confirming additive effects across the IRF5 haplotype blocks.

In primary Sjögren's syndrome, a Scandinavian study found strong associations with all three polymorphisms in the IRF5 risk haplotype | ORs >1.4 for each, P<0.01, with the IRF5 and STAT4 risk alleles acting in a striking additive fashion — individuals carrying all five IRF5 + STAT4 risk alleles had an OR of 6.78. For rheumatoid arthritis, the picture is more complex: a Slovakian case-control study (499 RA patients, 894 controls) | Vernerova et al. 2016 found rs10488631-C enriched in ACPA-positive and RF-positive RA (combined IRF5/CD28 risk variant burden discriminated seropositive from seronegative RA), while a Swedish cohort study found preferential association with seronegative RA | RF-negative: OR 1.24; ACPA-negative: OR 1.27, suggesting context-dependent effects.

Beyond rheumatic disease, GWAS identified the IRF5-TNPO3 locus as a primary biliary cirrhosis susceptibility locus | Combined P=8.66×10⁻¹³ across discovery and replication datasets, further establishing IRF5 as a pan-autoimmune risk gene across organ systems.

Practical Implications

Carrying the C allele, particularly one or two copies, indicates an immune system primed toward higher baseline interferon activity. This doesn't predetermine disease — most C carriers remain healthy — but it means early signs of autoimmune conditions should be evaluated promptly rather than monitored passively. The interferon pathway is central to both anti-viral defense and autoimmune pathogenesis; what protects against infections can, in excess, attack self-tissues.

The C allele is the molecular basis for the well-characterized interferon signature | Elevated expression of hundreds of IFN-inducible genes detected in blood of lupus and other autoimmune disease patients measurable in blood, and is detectable even before overt autoimmune disease develops. This has clinical relevance: in SLE, the interferon signature predates clinical diagnosis and correlates with disease activity. IRF5 variants have been hypothesized as potential predictors of response to anti-interferon biologics such as anifrolumab (approved for SLE), though prospective pharmacogenomic validation is still needed.

Interactions

The rs10488631 haplotype interacts additively with STAT4 (rs7574865), which encodes the signal transducer that responds to IFN-α downstream of IRF5. IRF5 drives interferon production while STAT4 amplifies cellular responsiveness to that interferon — a feed-forward amplification loop. Studies in primary Sjögren's syndrome demonstrated that each additional risk allele across IRF5 and STAT4 increased disease OR by ~1.78 on average, with the full five-allele combination reaching OR=6.78 | Nordmark et al. 2009, Genes & Immunity; P=2.5×10⁻⁹ for additive trend. Similar additive effects were documented in SLE.

Within the IRF5 locus, rs10488631 operates as part of a three-block haplotype system alongside rs2004640 (exon 1B splice site, documented separately) and rs4728142 (promoter CGGGG indel). The combination of all three risk haplotype blocks in a single individual substantially elevates autoimmune risk beyond the effect of any single variant. The presence of disease-specific autoantibodies (anti-dsDNA, anti-RBP in lupus; anti-SSA/SSB in Sjögren's) appears to interact with IRF5 risk genotype to amplify serum interferon activity, suggesting that the IFN-amplifying genotype becomes most pathogenic once autoreactive antibody production is established.